whitepaper
Whitepaper: The impacts of Brexit on the bio/pharmaceutical industry
On 23 June 2016, the decision was made on the European Union referendum for the United Kingdom to withdraw from the European Union.
List view / Grid view
Brexit
article
Issue 5, 2018
In this issue: LC-MS multi-attribute methods for the characterising and QC testing therapeutics, integrating data from Quality Control and Production to enable fast and informed decisions, and Solid-state NMR spectroscopy: using freeze drying to predict the stability of biological products.
news
Pharma firms step up plans to beat Brexit supply chain disruption
The EMA has revised downwards the number of medicines expected to face Brexit-related supply disruptions from 108, earlier this year, to a current level of 39...
article
US perspective on the impact of Brexit on the pharmaceutical sector
As the UK prepares to withdraw from the EU on 29th March 2019 at 23:00, this article delivers a US perspective on what Brexit is likely to mean for pharmaceutical companies.
news
UK-US post-Brexit trade deal risks increased drug prices
A trade deal between the UK and USA could risk increasing drug prices in the UK, which could diminish the affordability and accessibility of the NHS...
news
EMA’s building approval process in Amsterdam initiated
New permanent building to be completed by 15 November 2019...
news
EMA discusses future Amsterdam premises
The EMA Management Board have met in an extraordinary session to discuss EMA’s future premises in Amsterdam...
news
Patients must get the medicine they need after Brexit
Patients could find that supplies of their medicines will be disrupted when the UK leaves the EU, according to a new briefing published by the Brexit Health Alliance...
news
EMA surveys pharma companies on their preparedness for Brexit
The EMA is launching a survey to gather information from companies on their Brexit preparedness plans and identify any particular concerns with regard to medicines supply that may impact public or animal health...
news
UK Life Sciences firms struggle in post-Brexit war for EU talent
Following the Brexit vote, the UK is already seeing problems in filling senior positions at life sciences companies, with their average “slate” of candidates falling from around 40% non-UK nationals to just 15% non-UK candidates on average...
article
The impact of Brexit on life sciences
On 30 March 2019 the UK is set to leave the European Union (EU), a process that has become popularly known as Brexit. One little talked-about aspect of this move in the mainstream media is the impact it will have on the British life science community. Researchers and industry leaders…
news
Joint policy document shows the potential impact of Brexit
The associations representing the European and British life science industry have launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union...
news
Report highlights pharma’s key role in Scotland’s economy
Following new Fraser of Allander Institute analysis, the new Director of ABPI Scotland has called upon the Scottish Government to continue to support and prioritise strategic investments in Scotland’s research, development and manufacturing capabilities...
news
Budget 2017: Reaction from the UK’s pharmaceutical industry
The Chief Executive of the Association of the British Pharmaceutical Industry (ABPI), Mike Thompson responds to the UK’s Budget announcement...
news
EMA to relocate to Amsterdam, the Netherlands
The EMA will relocate to Amsterdam in the Netherlands. The Agency now has just over 16 months to prepare for the move and take up its operations in Amsterdam on 30 March 2019 at the latest...
